论文部分内容阅读
目的集成MR-PET设备的混合成像技术的发展开辟了神经肿瘤成像的新领域。仅采用常规MR成像很难确定颅内胶质瘤的明确界限。对于化疗后的瘢痕组织、残余肿瘤组织与肿瘤复发的鉴别仍具有挑战性。肿瘤组织与周围结构,如锥体束之间的关系会影响神经外科的治疗方式。方法通过运用多种MR成像技术,例如扩散张量成像(DTI)、多体素氢质子MR波谱成像(MRSI)和功能MR成像(fMRI)可以丰富诊断信息。利用PET的代谢成像,特别是氨基酸示踪剂如18F-FET或11C-MET可以提示肿瘤范围和预测治疗后的反应。结果 MR-PET混合成像系统通过40～50min的一站式工作具有提供综合诊断信息的优势。这种联合成像方法能够以相同成像中心提供不同成像方式的数据,从而获得最佳的空间和时间配准。所有的影像均在相同的生理条件下获得。结论详细介绍了成像方案,并且提供了采用不同成像方式如,FET-PET、常规结构像(T1加权像、T2加权像和T1对比增强成像)、DTI、MRSI和fMRI进行检查的病例。
The development of mixed imaging techniques for the purpose of integrating MR-PET devices opens up new areas of neuro-tumor imaging. It is difficult to determine the definite boundaries of intracranial gliomas only with conventional MR imaging. For post-chemotherapy scar tissue, the identification of residual tumor tissue and tumor recurrence remains challenging. The relationship between the tumor tissue and its surrounding structures, such as the pyramidal tract, affects neurosurgical treatment. Methods The diagnostic information can be enriched using a variety of MR imaging techniques such as diffusion tensor imaging (DTI), multi-voxel proton MR spectroscopy (MRSI) and functional MR imaging (fMRI). Metabolic imaging with PET, particularly amino acid tracers such as 18F-FETs or 11C-MET, may suggest a range of tumors and predict post-treatment response. Results The MR-PET hybrid imaging system has the advantage of providing comprehensive diagnostic information through one-stop work of 40-50 minutes. This combined imaging approach provides data from different imaging modalities at the same imaging center for optimal spatial and temporal registration. All images were obtained under the same physiological conditions. Conclusion The imaging protocol was described in detail, and cases were examined using different imaging modalities such as FET-PET, conventional structural images (T1 weighted images, T2 weighted images and T1 contrast enhanced imaging), DTI, MRSI and fMRI.